Table 1 Characteristics of patients in routine and inception cohorts
Characteristic | Routine cohort (cross-sectional) | Inception cohort (longitudinal) |
|---|---|---|
Patients (n) | 767 | 106 |
Age (years; mean ± SD) | 54.1 ± 14.9 | 50.5 ± 15.6 |
Sex (% female) | 79.9 | 75.2 |
Rheumatoid factor (% positive) | 55.3 | 78.1 |
Disease duration at baseline (mean ± SD) | 8.1 ± 10.6 years | 11.5 ± 12.5 weeks |
Duration of follow up (years; mean ± SD; range) | - | 3.2 ± 1.3; 1–7.25 |
Disease activity characteristics (median [1st;3rd quartile]) | At cross-section | At baseline |
Swollen joint count (0–28) | 3 (1;7) | 7 (4;13) |
Tender joint count (0–28) | 2 (0;6) | 8 (3;16) |
ESR (mm; normal <20) | 23 (14;55) | 49 (24;70) |
CRP (mg/dl; normal <1.0) | 1.1 (0.5;2.7) | 5.1 (1.9;17.0) |
Patient assessment of pain (mm; 0–100) | 37 (19;53) | 50 (32;66) |
Patient global assessment of activity (mm; 0–100) | 37 (18;58) | 51 (33;66) |
Evaluator global assessment of activity (mm; 0–100) | 34 (19;49) | 44 (31;58) |
HAQ (0–3) | 0.875 (0.25;1.5) | 0.75 (0;1.5) |
Larsen score | - | 1 (0;7) |
Completeness of data for analysis | Â | Â |
Cross-sectional correlation between composite indices (n [%]) | 767/767 (100)a | 105/106 (99.1%)b |
Cross-sectional correlation with HAQ scores (n [%]) | 720/767 (93.9) | 104/106 (98.1)b |
Discriminant validity, 1-year follow up (n [%]) | - | 91/100 (91.0%) |
Construct validity, 3-year follow upc (n [%]) | - | 56/80 (70.0%) |